Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis

Abstract

The present invention is directed to orally administered compositions of topically acting corticosteroids for the treatment of inflammation of the gastrointestinal tracts such as eosinophilic esophagitis. The present invention also provides a method for treating conditions associated with inflammation of the gastrointestinal tract in an individual. The method comprises administering to an individual in need thereof a pharmaceutical composition of the present invention as orally disintegrating tablets comprising a topically active corticosteroid adsorbed onto a pharmaceutically acceptable carrier such as silicified microcrystalline cellulose.

What is claimed is: 
     
         1 . A batch of orally dispersing tablets, each orally disintegrating tablet comprising drug particles comprising budesonide adsorbed onto a pharmaceutically acceptable carrier; and
 wherein each orally disintegrating tablet comprises about 0.5 mg to about 3 mg of budesonide, and the budesonide has a mean particle size ranging from about 100 nm to about 100 μm;   wherein each orally disintegrating tablet comprises sucralose, mannitol, magnesium stearate, polyvinyl pyrrolidone, or combinations thereof   wherein the batch of orally disintegrating tablets has a content uniformity ranging from about 93.2% to about 100.4%; and   wherein each orally disintegrating tablet disintegrates within 60 seconds when tested using the USP <701> method for disintegration time.   
     
     
         2 . The batch of orally dispersing tablets of  claim 1 , wherein the pharmaceutically acceptable carrier is selected from the group consisting of microcrystalline cellulose, silicified microcrystalline cellulose, pregelatinized starch, corn starch, colloidal silica, and amorphous magnesium aluminum silicate. 
     
     
         3 . The batch of orally dispersing tablets of  claim 1 , wherein the pharmaceutically acceptable carrier is present at an amount of about 10% w/w based on the total weight of the orally disintegrating tablet. 
     
     
         4 . The batch of orally dispersing tablets of  claim 1 , wherein the batch of orally disintegrating tablets has a content uniformity within the range of about 97.5% (3.7% RSD). 
     
     
         5 . The batch of orally dispersing tablets of  claim 1 , wherein the batch of orally disintegrating tablets has a content uniformity within the range of about 99.2% (1.7% RSD). 
     
     
         6 . The batch of orally dispersing tablets of  claim 1 , wherein each orally disintegrating tablet has a friability 1.6% or less. 
     
     
         7 . The batch of orally dispersing tablets of  claim 1 , wherein each orally disintegrating tablet has a friability ranging from about 0.5-1%. 
     
     
         8 . The batch of orally dispersing tablets of  claim 1 , wherein each orally disintegrating tablet has a hardness ranging from about 1.3-4.9 kP. 
     
     
         9 . The batch of orally dispersing tablets of  claim 1 , wherein the orally disintegrating tablets have a potency ranging from about 95.4% to about 99.6%. 
     
     
         10 . The batch of orally dispersing tablets of  claim 1 , wherein each orally disintegrating tablet has a friability about 1% to about 0.5%, a hardness ranging about 1.3-4.9 kP, and a potency ranging from about 95.4% to about 99.6%. 
     
     
         11 . The batch of orally dispersing tablets of  claim 1 , wherein budesonide is present in an amount of about 0.5 mg in the orally disintegrating tablet. 
     
     
         12 . The batch of orally dispersing tablets of  claim 1 , wherein budesonide is present in an amount of about 1 mg in the orally disintegrating tablet. 
     
     
         13 . The batch of orally dispersing tablets of  claim 1 , wherein the budesonide has a mean particle size ranging from about 100 nm to about 10 μm. 
     
     
         14 . The batch of orally dispersing tablets of  claim 1 , wherein:
 no more than about 0.8 wt. % of the drug particles have a particle size of 840 μm or greater,   no more than about 4.2 wt. % of the drug particles have a particle size of 425 μm or greater,   no more than about 14.8 wt. % of the drug particles have a particle size of 250 μm or greater,   no more than about 26.2 wt. % of the drug particles have a particle size of 180 μm or greater,   no more than about 32.3 wt. % of the drug particles have a particle size of 150 μm or greater, or   no more than about 56.7 wt. % of the drug particles have a particle size of 75 μm or greater.   
     
     
         15 . The batch of orally dispersing tablets of  claim 1 , wherein about 85.2 wt. % to about 92.4 wt. % of the drug particles have a particle size less than about 250 μm. 
     
     
         16 . The batch of orally dispersing tablets of  claim 1 , wherein about 67 wt. % to about 76 wt. % of the drug particles have a particle size less than about 150 μm. 
     
     
         17 . The batch of orally dispersing tablets of  claim 2 , wherein about 85.2 wt. % to about 92.4 wt. % of the drug particles have a particle size less than about 250 μm. 
     
     
         18 . The batch of orally dispersing tablets of  claim 2 , wherein about 67 wt. % to about 76 wt. % of the drug particles have a particle size less than about 150 μm. 
     
     
         19 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 0.8 wt. % of the drug particles have a particle size of 840 μm or greater. 
     
     
         20 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 4.2 wt. % of the drug particles have a particle size of 425 μm or greater. 
     
     
         21 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 14.8 wt. % of the drug particles have a particle size of 250 μm or greater. 
     
     
         22 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 26.2 wt. % of the drug particles have a particle size of 180 μm or greater. 
     
     
         23 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 32.3 wt. % of the drug particles have a particle size of 150 μm or greater. 
     
     
         24 . The batch of orally dispersing tablets of  claim 1 , wherein no more than about 56.7 wt. % of the drug particles have a particle size of 75 μm or greater. 
     
     
         25 . A method of treating eosinophilic esophagitis comprising administering the orally dispersing tablets of  claim 1 . 
     
     
         26 . The method of  claim 25 , wherein the orally disintegrating tablets have a potency ranging from about 95.4% to about 99.6%.